Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials

by Virtus | Jul 2, 2025

LONDON – VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa...

Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations.

by Virtus | Dec 6, 2019

Click the button below to read more about this. CLICK HERE FOR ARTICLE  ...

Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation.

by Virtus | Dec 6, 2019

Click the button below to read more about this. CLICK HERE FOR...

Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.

by Virtus | Nov 6, 2019

Click the button below to read more about this. CLICK HERE FOR...

Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production.

by Virtus | Nov 3, 2019

Click the button below to read more about this. CLICK HERE FOR...